<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Swerdlow NR</submitter><funding>NIA NIH HHS</funding><funding>RRD VA</funding><pagination>355-362</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12416332</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>91(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects.&lt;h4>Objective&lt;/h4>To begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.&lt;h4>Methods&lt;/h4>18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.&lt;h4>Results&lt;/h4>Fifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation</pubmed_abstract><journal>Journal of Alzheimer's disease : JAD</journal><pubmed_title>Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.</pubmed_title><pmcid>PMC12416332</pmcid><funding_grant_id>IK2 RX003395</funding_grant_id><funding_grant_id>IK1 RX003683</funding_grant_id><funding_grant_id>R01 AG059640</funding_grant_id><funding_grant_id>P30 AG062429</funding_grant_id><pubmed_authors>Molina JL</pubmed_authors><pubmed_authors>Sprock J</pubmed_authors><pubmed_authors>Delano-Wood L</pubmed_authors><pubmed_authors>Leger GC</pubmed_authors><pubmed_authors>Kotz JE</pubmed_authors><pubmed_authors>Joshi YB</pubmed_authors><pubmed_authors>Talledo J</pubmed_authors><pubmed_authors>Iwanaga D</pubmed_authors><pubmed_authors>Light GA</pubmed_authors><pubmed_authors>Huege S</pubmed_authors><pubmed_authors>Swerdlow NR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.</name><description>&lt;h4>Background&lt;/h4>The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects.&lt;h4>Objective&lt;/h4>To begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.&lt;h4>Methods&lt;/h4>18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.&lt;h4>Results&lt;/h4>Fifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-06-02T00:35:40.701Z</modification><creation>2026-05-24T03:07:50.647Z</creation></dates><accession>S-EPMC12416332</accession><cross_references><pubmed>36404550</pubmed><doi>10.3233/JAD-220769</doi><doi>10.3233/jad-220769</doi></cross_references></HashMap>